Best Selling Erythromycin A oxime CAS NO 13127-18-9 In Bulk Quantity

Here's a detailed description for Erythromycin A oxime (13127-18-9):

1. Introduction to Erythromycin A Oxime (13127-18-9) Erythromycin A oxime is a derivative of erythromycin, a broad-spectrum antibiotic belonging to the macrolide class. This compound is characterized by the addition of an oxime group (-NOH) to the erythromycin A molecule, resulting in a modified structure with potentially altered pharmacological properties.

2. Chemical Structure and Molecular Composition The molecular formula of erythromycin A oxime is C38H67NO13, representing a complex macrocyclic lactone ring structure with an additional oxime moiety attached to the molecule. This modification introduces new functional groups and alters the chemical properties of the parent compound, potentially influencing its biological activity and pharmacokinetics.

3. Synthesis and Production Erythromycin A oxime can be synthesized through chemical modification of erythromycin A using appropriate reagents and reaction conditions. The oximation reaction involves the addition of hydroxylamine to the carbonyl group of the erythromycin A molecule, resulting in the formation of the oxime derivative. Commercially, it may be produced on a laboratory scale for research purposes or as a precursor for further chemical transformations.

4. Pharmacological Properties Erythromycin A oxime retains the antibacterial activity characteristic of erythromycin and other macrolide antibiotics. It exerts its therapeutic effects by inhibiting bacterial protein synthesis through binding to the 50S ribosomal subunit, thereby disrupting bacterial growth and replication. The addition of the oxime group may alter the pharmacokinetic profile, bioavailability, or spectrum of activity of the parent compound, potentially enhancing its therapeutic efficacy or reducing adverse effects.

5. Antibacterial Spectrum and Clinical Applications As a derivative of erythromycin, erythromycin A oxime is effective against a wide range of Gram-positive and some Gram-negative bacteria, as well as certain atypical pathogens. It is commonly used in the treatment of respiratory tract infections, skin and soft tissue infections, and genitourinary tract infections caused by susceptible bacteria. However, its use may be limited by the emergence of bacterial resistance or adverse effects such as gastrointestinal disturbances or allergic reactions.

6. Pharmacokinetics and Metabolism The pharmacokinetic properties of erythromycin A oxime, including absorption, distribution, metabolism, and elimination, may vary depending on the route of administration, formulation, and patient factors. Following oral administration, it is rapidly absorbed from the gastrointestinal tract and distributed to various tissues and body fluids. Metabolism occurs primarily in the liver, with metabolites excreted in the bile and urine. The addition of the oxime group may influence the metabolic pathways or pharmacokinetic parameters of the compound compared to the parent erythromycin.

7. Safety and Adverse Effects Like other macrolide antibiotics, erythromycin A oxime is generally well tolerated, with a favorable safety profile in most patients. However, adverse effects such as gastrointestinal disturbances (e.g., nausea, vomiting, diarrhea), hepatotoxicity, and allergic reactions may occur, particularly with prolonged or high-dose therapy. Patients with known hypersensitivity to erythromycin or other macrolides should avoid its use, and caution is advised in individuals with pre-existing liver or renal impairment.

8. Drug Interactions Erythromycin A oxime may interact with other medications, including drugs metabolized by the cytochrome P450 enzyme system, such as certain statins, anticoagulants, and benzodiazepines. Concurrent use with these medications may result in altered plasma concentrations, efficacy, or toxicity, necessitating dose adjustments or careful monitoring. Patients should inform their healthcare provider about all prescription, over-the-counter, and herbal medications they are taking before initiating therapy with erythromycin A oxime.

9. Research and Development Ongoing research efforts focus on elucidating the pharmacological properties, mechanism of action, and therapeutic potential of erythromycin A oxime, as well as exploring its use in combination therapy or for the treatment of emerging drug-resistant bacterial infections. Additionally, efforts are underway to develop novel formulations or delivery systems to improve the bioavailability, stability, and patient adherence to erythromycin A oxime therapy.

10. Conclusion: Potential Antibacterial Agent with Modified Properties In conclusion, erythromycin A oxime represents a modified derivative of erythromycin with potential applications as an antibacterial agent in the treatment of various infections. Its addition of the oxime group introduces structural changes that may influence its pharmacological properties, including efficacy, safety, and pharmacokinetics. Further research is warranted to fully elucidate the therapeutic potential and clinical utility of erythromycin A oxime in the management of bacterial infections and related conditions.